NIH Hears Arguments Over Compulsory License For AIDS Drug

Law360, New York (May 25, 2004, 12:00 AM EDT) -- Patient advocates and industry officials clashed at a meeting at the National Institutes of Health Tuesday to debate whether the U.S. government should issue compulsory license for an AIDS drug produced by Abbott Laboratories.

In December, Abbott Labs raised the wholesale price for a month's worth of the protease inhibitor Norvir, widely used in small doses to boost the potency of some AIDS combination-drug therapies, to $265 from $54.

The move caused an avalanche of protests from AIDS activists, who demanded a public meeting to consider...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.